Eric Jonasch, Md, On Integrating Immunotherapies Into Renal Cell Carcinoma Treatment Algorithms

Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms

Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma

What can patients do to mitigate side effects from kidney cancer treatment?

Kidney Cancer Association

Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma

Targeted Therapies For The Treatment Of Kidney Cancer, Eric Jonasch, MD

ESMO22 Highlights: Dr. Jonasch Discusses the COSMIC313 Trial for Kidney Cancer

Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy

Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

Dr. Jonasch on Single-Agent Pembrolizumab in Non-Clear Cell RCC

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

#KCRS19: Eric Jonasch, M.D.

Frontline Treatment For Renal Cell Carcinoma - Eric Jonasch

Brain Metastases and Kidney Cancer: Insights from Dr. Eric Jonasch (MD Anderson Cancer Center)

What Are The Next Therapies On The Horizon For The Treatment Of Kidney Cancer? Eric Jonasch, MD

Dr. Jonasch on Alternative Sunitinib Scheduling for mRCC

Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in

Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy

Systemic targeted therapy for metastatic renal cell carcinoma in 2012 Eric Jonasch, M.D

Dr. Jonasch on Modulating the Tumor Microenvironment in RCC

Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC